Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
What should define a SARS-CoV-2 “breakthrough” infection?
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
Published May 11, 2021
Citation Information: J Clin Invest. 2021;131(12):e151186. https://doi.org/10.1172/JCI151186.
View: Text | PDF
Viewpoint

What should define a SARS-CoV-2 “breakthrough” infection?

  • Text
  • PDF
Abstract

Authors

John S. Schieffelin, Elizabeth B. Norton, Jay K. Kolls

×

Figure 1

Clinical scenarios and proposed classification of breakthrough infection based on disease in the lower respiratory tract.

Options: View larger image (or click on image) Download as PowerPoint
Clinical scenarios and proposed classification of breakthrough infection...
We propose that breakthrough infection after COVID-19 vaccination is defined by evidence of lower respiratory tract infection (LRI) and a positive PCR test for SARS-COV-2. Vaccinated individuals who are asymptomatic or have symptoms limited to an upper respiratory tract infection (URI) are not experiencing a breakthrough infection, although it is important to understand that these individuals may still be able to transmit virus. We also suggest that those individuals who do not mount an effective immune response to vaccination do not represent cases of breakthrough infection. *Transmission risk is likely proportionate to the viral copy number.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts